Apomorphine hydrochloride for the treatment of Parkinson’s disease

References

• Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2006;373:2055-66
   Google Scholar
• Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 2003;26:196-8
   PubMedGoogle Scholar
• Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 2005;20:224-30
   PubMed Web of Science ®Google Scholar
• Doi H, Sakakibara R, Sato M, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson’s disease. J Neurol Sci 2012;319:86-8
   PubMed Web of Science ®Google Scholar
• Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson’s disease. Mov Disord 2014;29:23-32
   PubMed Web of Science ®Google Scholar
• Fernandez N, Garcia JJ, Diez MJ, et al. Effects of dietary factors on levodopa pharmacokinetics. Expert Opin Drug Metab Toxicol 2010;6:633-42
   PubMed Web of Science ®Google Scholar
• Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 2013;28:1241-9
   PubMed Web of Science ®Google Scholar
• Isaacson S, Chaudhuri KR. Morning akinesia and the potential role of gastroparesis –managing delayed onset of first daily dose of oral levodopa in patients with Parkinson’s disease. Eur Neurolog Rev 2013;8:82-4
   Google Scholar
• Kulizewsky J, Luquin MR, Arbelo JM, et al. Advanced Parkinson’s disease: clinical characteristics and treatment. Part II. Neurología 2013;28:558-83
   PubMedGoogle Scholar
• Swope DM. Rapid treatment of “wearing–off” in Parkinson’s disease. Neurology 2004;62:S27-31
   PubMed Web of Science ®Google Scholar
• Muguet D, Broussolle E, Chazot G. Apomorphine in patients with Parkinson’s disease. Biomed Pharmacother 1995;49:197-209
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Subcutaneously administered apomorphine. Pharmacokinetics and metabolism. Neurology 2004;62:S8-S11
   Google Scholar
• Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-8
   PubMed Web of Science ®Google Scholar
• Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease. Clin Pharmacokinet 2006;45:109-36
   PubMed Web of Science ®Google Scholar
• Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 1951;56:251-3
   PubMedGoogle Scholar
• Cotzias GC, Papavasilious PS, Fehling C, et al. Similarities between neurological effects of L–dopa and apomorphine. N Engl J Med 1970;282:31-3
   PubMed Web of Science ®Google Scholar
• Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1979;51:954-6
   Google Scholar
• Bonuccelli U, Piccini P, Del Dotto P, et al. “Apomorphine test for dopaminergic responsiveness: a dose assessment study”. Mov Disord 1993;8:158-64
   PubMed Web of Science ®Google Scholar
• Roth J, Ruzicka E, Mecir P. The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience. Cas Lek Cesk 1994;133:665-7
   PubMedGoogle Scholar
• Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000;69:590-4
   PubMedGoogle Scholar
• Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa–induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord 1992;7:117-24
   PubMed Web of Science ®Google Scholar
• Hardie RJ, Lees AJ, Stern GM. On–off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain 1984;107:487-506
   PubMed Web of Science ®Google Scholar
• Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on–off oscillations. Lancet 1988;1:403-6
   PubMed Web of Science ®Google Scholar
• Kempster PA, Frankel JP, Stern GM, Lees AJ. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990;53:1004-7
   PubMed Web of Science ®Google Scholar
• Van Laar T. A double–blind study of the efficacy of apomorphine and its assessment in “off”–periods in Parkinson’s disease. Clin Neurol Neurosurg 1993;95:231-5
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58:681-7
   PubMed Web of Science ®Google Scholar
• Merello M, Pikielny R, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson’s disease patients: a double blind single–dose study. Clin Neuropharmacology 1997;20:165-7
   PubMed Web of Science ®Google Scholar
• Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990;53:96-101
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: Response to chronic administration for up to five years. Mov Disord 1993;8:165-70
   PubMed Web of Science ®Google Scholar
• Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late state Parkinson’s disease: A longterm follow up. J Neurol Neurosurg Psychiatry 1998;65:709-16
   PubMed Web of Science ®Google Scholar
• Dewey RBJr, Hutton JT, LeWitt PA, Factor SA. A randomized, double–blind, placebo–controlled trial of subcutaneously injected apomorphine for parkinsonian off–state events. Arch Neurol 2001;58:1385-92
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF, Gutmann L, Hull KLJr, et al. The APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord 2007;13:93-100
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord 2008;14:85-92
   PubMed Web of Science ®Google Scholar
• Pahwa R, Koller WC, Trosch RM, Sherry JH. APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: A dose–escalation study with randomized, double–blind, placebo–controlled crossover evaluation of a single dose. J Neurol Sci 2007;258:137-43
   PubMed Web of Science ®Google Scholar
• Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for ‘off’ episodes in Parkinson’s disease: a 6–month open–label study. CNS Drugs 2008;22:519-27
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Ondo WG, Van Lunen B, Bottini PB. Open–label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease. Clin Neuropharmacol 2009;32:89-93
   PubMed Web of Science ®Google Scholar
• Isaacson S. Apomorphine penject – emerging evidence and treatment strategies for delayed On and Off periods in Parkinson’s disease. Eur Med J Neurol 2014;1:27-35
   Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence–based review of its use in Parkinson’s disease. Drugs Aging 2004;21:687-709
   PubMed Web of Science ®Google Scholar
• Lertxundi U, Domingo-Echaburu S, Soraluce A, et al. Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard? Curr Drug Saf 2013;8:63-8
   PubMedGoogle Scholar
• Chaudhuri KR, Healy D, Schapira AHV. The non–motor symptoms of Parkinson’s disease. Diagnosis and management. Lancet Neurol 2006;5:235-45
   PubMed Web of Science ®Google Scholar
• Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol 1989;46:1061-4
   PubMedGoogle Scholar
• Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol 1993;33:490-3
   PubMed Web of Science ®Google Scholar
• Rossi M, Merello M, Perez–Lloret S. Management of constipation in Parkinson’s disease. Expert Opin Pharmacother 2014;16:4
   Google Scholar
• Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord 1996;11:729-32
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson’s disease. Mov Disord 2006;21:727-8
   PubMed Web of Science ®Google Scholar
• Tribl GG, Sycha T, Kotzailias N, et al. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatr 2005;76:181-5
   PubMed Web of Science ®Google Scholar
• Haba–Rubio J, Staner L, Cornette F, et al. Acute low single dose of apomorphine reduces periodic limb movements but has no significant effect on sleep arousals: a preliminary report. Neurophysiol Clin 2003;33:180-4
   PubMed Web of Science ®Google Scholar
• Priano L, Albani G, Brioschi A, et al. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1–night transdermal apomorphine treatment. Neurol Sci 2003;24:207-8
   PubMedGoogle Scholar
• Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-3
   PubMed Web of Science ®Google Scholar
• Magennis B, Cashell A, O’Brien D, Lynch T. An audit of apomorphine in the management of complex idiopathic Parkinson’s disease in Ireland. Mov Disord 2012;27:S44
   Google Scholar
• Todorova A, Martin A, Okai D, et al. Assessment of impulse control disorders in Parkinson’s patients with infusion therapies: a single centre experience. Mov Disord 2013;28:S133
   Google Scholar
• Garcia-Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long–term continuous subcutaneous– apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicentre study. Mov Disord 2008;23:1130-6
   PubMedGoogle Scholar
• Corsini GU, Pitzalis GF, Bemardi F, et al. The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology 1981;20:1309-13
   PubMedGoogle Scholar
• Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 1997;3:103-7
   PubMedGoogle Scholar
• Ahmad N, Keith–Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 2006;6:571-6
   PubMed Web of Science ®Google Scholar
• Cameron HA, Reyntjens AJ, Lake–Bakaar G. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 1985;290:160
   PubMed Web of Science ®Google Scholar
• Giaccone G, Berletto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 1984;2:1336-7
   PubMed Web of Science ®Google Scholar
• Osborne RJ, Sleven ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone. Lancet 1985;2:385
   PubMed Web of Science ®Google Scholar
• Johannes CB, Varas–Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case–control study. Pharmacoepidemiol Drug Saf 2010;19:881-8
   PubMed Web of Science ®Google Scholar
• Domperidone: small risk of serious ventricular arrhythmia and sudden cardiac death. Drug Saf Update 2012;5:A2
   Google Scholar
• Chen JJ, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associate with advanced Parkinson’s disease. Clin Ther 2005;27:1710-24
   PubMed Web of Science ®Google Scholar
• Hauser RA, Isaacson S, Clinch T; The Tigan/Apokyn Study Investigators. Randomized, placebo–controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 2014;20:1171-6
   PubMed Web of Science ®Google Scholar
• Deffond D, Durif F, Tournillac M. Apomorphine in treatment of Parkinson’s disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry 1993;56:101-3
   PubMed Web of Science ®Google Scholar
• Dewey RB, Maraganore DM, Ahlskog JE, Matsumoto JY. A. double–blind, placebo–controlled study of intranasal apomorphine spray as a rescue agent for Off–States in Parkinson’s disease. Mov Disord 1998;13:782-7
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Phase IIa randomized double–blind, placebo–controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson’s disease. Eur J Neurol 2013;20:1445-50
   PubMed Web of Science ®Google Scholar
• Todorova A, Chaudhuri KR. Subcutaneous apomorphine and non–motor symptoms in Parkinson’s Disease. Parkinsonism Relat Disord 2013;19:1073-8
   PubMed Web of Science ®Google Scholar
• Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W. Subcutaneous apomorphine in Parkinson’s disease. Lancet 1988;1:943
   PubMedGoogle Scholar
• Pollak P, Champay AS, Hommel M, et al. Subcutaneous apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989;52:544
   PubMed Web of Science ®Google Scholar
• Poewe W, Kleedorfer B, Wagner M, et al. Side–effects of subcutaneous apomorphine in Parkinson’s disease. Lancet 1989;1:1084-5
   PubMedGoogle Scholar
• Hughes AJ, Lees AJ, Stern GM. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991;54:358-60
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Bishop S, Stern GM, Lees AJ. The motor response to repeated apomorphine administration in Parkinson’s disease. C/in Neuropharmacol 1991;14:209-13
   PubMed Web of Science ®Google Scholar
• Gervason CL, Pollak PR, Limousin P, Perret JE. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson’s disease. Clin Neuropharmacol 1993;16:113-19
   PubMed Web of Science ®Google Scholar